SPEX - Spherix Incorporated

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.2801
+0.0001 (+0.0078%)
At close: 3:57PM EST
Stock chart is not supported by your current browser
Previous Close1.2800
Open1.3200
Bid1.0100 x 400
Ask1.5500 x 700
Day's Range1.2800 - 1.3300
52 Week Range0.8900 - 4.7500
Volume82,684
Avg. Volume254,603
Market Cap7.981M
Beta-1.35
PE Ratio (TTM)N/A
EPS (TTM)-1.2040
Earnings DateN/A
Forward Dividend & Yield0.00 (0.00%)
Ex-Dividend Date1980-05-12
1y Target Est19.00
Trade prices are not sourced from all markets
  • Spherix Holds Annual Shareholder Meeting
    PR Newswire3 days ago

    Spherix Holds Annual Shareholder Meeting

    Announces Intent to Distribute Stock Dividend in 2018 NEW YORK , Dec. 13, 2017 /PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEX) a technology development company committed to the fostering of innovative ...

  • PR Newswire12 days ago

    Hoth Therapeutics Inc. Announces Issuance of First U.S. Patent on Its BioLexa Platform

    Patent Covers Proprietary Compositions for Eczema Treatment NEW YORK , Dec. 4, 2017 /PRNewswire/ -- Hoth Therapeutics Inc. ("Hoth" or the "Company"), a development stage biopharmaceutical ...

  • Have Investors Already Priced In Service Growth For Spherix Incorporated (SPEX)?
    Simply Wall St.29 days ago

    Have Investors Already Priced In Service Growth For Spherix Incorporated (SPEX)?

    Spherix Incorporated (NASDAQ:SPEX), a USD$8.42M small-cap, is a professional services company operating in an industry, which generally follows the ups and downs of the economic cycle, as its services caterRead More...

  • Spherix Announces Sponsorship of Student-Led Artificial Intelligence and Super Computing Initiative
    PR Newswirelast month

    Spherix Announces Sponsorship of Student-Led Artificial Intelligence and Super Computing Initiative

    NEW YORK, Nov. 8, 2017 /PRNewswire/ -- Spherix Incorporated ("Spherix" or the "Company") (SPEX), a technology development company committed to the fostering of innovative ideas, today announced the sponsorship of the Shark Tank initiative at the College of William & Mary in Virginia.  William & Mary is a cutting-edge research university and is the second-oldest institution of higher education in the United States.

  • Spherix Incorporated (SPEX): Time For A Financial Health Check
    Simply Wall St.last month

    Spherix Incorporated (SPEX): Time For A Financial Health Check

    Spherix Incorporated (NASDAQ:SPEX) is a small-cap stock with a market capitalization of USD $8.35M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, theyRead More...

  • PR Newswire2 months ago

    Hoth Therapeutics Inc. Announces the Addition of Dr. Richard D Granstein, M.D. to the Company's Technology Advisory Board

    NEW YORK, Oct. 16, 2017 /PRNewswire/ -- Hoth Therapeutics Inc., a Nevada corporation ("Hoth" or  the "Company"), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema, announced today the addition of Dr. Richard D. Granstein, M.D., to the Company's Technology Advisory Board.  The Technology Advisory Board was formed to assist the Company in developing the BioLexa Platform.  The BioLexa Platform is a proprietary, patented, drug compound platform developed at the University of Cincinnati.

  • PR Newswire3 months ago

    Hoth Therapeutics Inc. Announces the Addition of Dr. Andrew Herr to the Company's Technology Advisory Board

    NEW YORK, Sept. 5, 2017 /PRNewswire/ -- Hoth Therapeutics Inc., a Nevada corporation ("Hoth" or the "Company"), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema, announced today the addition of Dr. Andrew Herr, PhD, to the Company's Technology Advisory Board.  The Technology Advisory Board was formed to assist the Company in developing the BioLexa Platform.  The BioLexa Platform is a proprietary, patented, drug compound platform developed at the University of Cincinnati.

  • Spherix Announces the Addition of Dr. Scott T. Tagawa to Company's Technology Advisory Board
    PR Newswire4 months ago

    Spherix Announces the Addition of Dr. Scott T. Tagawa to Company's Technology Advisory Board

    NEW YORK, Aug. 15, 2017 /PRNewswire/ -- Spherix Incorporated ("Spherix" or the "Company") (SPEX), an intellectual property development company committed to the fostering of technology, today announced the addition of Dr. Scott T. Tagawa to the Company's Technology Advisory Board.  The Technology Advisory Board was formed to assist the Company in evaluating potential opportunities in the biopharmaceutical arena. Dr. Scott T. Tagawa, MD, MS is the Richard A. Stratton Associate Professor in Hematology and Oncology and an Associate Professor of Clinical Medicine and of Clinical Urology at Weill Cornell Medicine.

  • Spherix Issues Letter to Shareholders
    PR Newswire4 months ago

    Spherix Issues Letter to Shareholders

    NEW YORK, Aug. 2, 2017 /PRNewswire/ -- Spherix Incorporated (SPEX) an intellectual property development company committed to fostering of technology, today issued a letter to shareholders. It is with great pleasure that I take this opportunity to update you on recent events at the Company and describe in greater detail our strategic path forward.   The fundamentals at Spherix are stronger than they have been in recent memory and our path to value creation is moving forward with precision and focus.

  • Spherix Announces That Anthony Hayes Joins the Board of Directors at Hoth Therapeutics Inc.
    PR Newswire5 months ago

    Spherix Announces That Anthony Hayes Joins the Board of Directors at Hoth Therapeutics Inc.

    NEW YORK, July 27, 2017 /PRNewswire/ -- Spherix Incorporated ("Spherix" or the "Company") (SPEX), an intellectual property development company committed to fostering of technology, today announced that Anthony Hayes, CEO of Spherix Inc., joins the board of directors at Hoth Therapeutics Inc.

  • Spherix Announces the Formation of a Technology Advisory Board in Area of BioPharmaceutical Opportunities
    PR Newswire5 months ago

    Spherix Announces the Formation of a Technology Advisory Board in Area of BioPharmaceutical Opportunities

    NEW YORK, July 25, 2017 /PRNewswire/ -- Spherix Incorporated ("Spherix" or the "Company") (SPEX), an intellectual property development company committed to the fostering of technology, today announced the formation of a Technology Advisory Board in the area of biopharmaceutical opportunities. The Technology Advisory Board was formed to assist the Company in evaluating potential opportunities in the biopharmaceutical arena, as well as to advise the Company in its work with Hoth Therapeutics. As previously reported, the Company recently acquired a controlling interest in Hoth Therapeutics, a company involved in the development of a novel topical treatment for patients suffering from atopic dermatitis, such as eczema.  Individuals serving on the advisory board will provide the Company advice, support and technical assistance in reviewing diversification opportunities.

  • Spherix Announces Closing Of Public Offering Of Common Stock
    PR Newswire5 months ago

    Spherix Announces Closing Of Public Offering Of Common Stock

    NEW YORK, July 24, 2017 /PRNewswire/ -- Spherix Incorporated ("Spherix" or the "Company") (SPEX), an intellectual property development company committed to fostering of technology, today announced that it has closed its previously announced firm commitment underwritten public offering of 1,250,000 shares of its common stock at a price to the public of $2.00 per share. After deducting the underwriter's discount and other offering expenses payable by Spherix, the net proceeds to the Company are approximately $2.1 million.

  • Spherix Announces Pricing of Public Offering of Common Stock
    PR Newswire5 months ago

    Spherix Announces Pricing of Public Offering of Common Stock

    NEW YORK, July 19, 2017 /PRNewswire/ -- Spherix Incorporated ("Spherix" or the "Company") (SPEX), an intellectual property development company committed to fostering of technology and monetization of intellectual property, today announced that it has priced a firm commitment underwritten public offering of 1,250,000 shares of its common stock at a price to the public of $2.00 per share. In addition, Spherix has granted the underwriter a 45-day option to purchase up to 187,500 additional shares of common stock to cover over-allotments, if any.

  • Spherix Inc. Announces Closing of the Deal with Hoth Therapeutics
    PR Newswire5 months ago

    Spherix Inc. Announces Closing of the Deal with Hoth Therapeutics

    Spherix Incorporated Acquires 6,800,000 shares of Hoth Therapeutics NEW YORK , July 3, 2017 /PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEX) reported today, following the disclosure made June 20 th ...

  • PR Newswire6 months ago

    Spherix Issues Letter to Shareholders

    NEW YORK, June 27, 2017 /PRNewswire/ -- Spherix Incorporated (SPEX) an intellectual property development company committed to the fostering of technology and monetization of intellectual property, today issued a letter to shareholders. With that in mind, I'm going to provide you with more information on the transaction and update you on why we believe this transaction has positioned Spherix for growth.  I want each of you to know that I see the fundamentals at Spherix stronger than at any time in the last few years and our path to value creation is moving forward with focus.

  • Spherix Inc. Announces Definitive Terms Reached to Acquire Controlling Interest in Hoth Therapeutics, a Biopharmaceutical Company Developing its BioLexa Platform to Treat Skin Illness Such as Eczema.
    PR Newswire6 months ago

    Spherix Inc. Announces Definitive Terms Reached to Acquire Controlling Interest in Hoth Therapeutics, a Biopharmaceutical Company Developing its BioLexa Platform to Treat Skin Illness Such as Eczema.

    Hoth's BioLexa platform uses its proprietary technology to treat eczema without the use of traditional topical steroids. NEW YORK, June 20, 2017 /PRNewswire/ -- Spherix Incorporated (SPEX) announced today that the Company has negotiated definitive terms to acquire a controlling interest in Hoth Therapeutics, a development stage biopharmaceutical company focused on the development of therapeutics for patients suffering from atopic dermatitis, such as eczema.  Closing of the deal with Hoth is subject to the completion and execution of customary closing documents, which the Company expects to be completed within 30 days or less.

  • Spherix, Inc. :SPEX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
    Capital Cube6 months ago

    Spherix, Inc. :SPEX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017

    Categories: Yahoo FinanceGet free summary analysis Spherix, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Spherix, Inc. – RPX Corporation, FORM Holdings Corp., Acacia Research Corporation, Charter Communications, Inc. Class A and Lightbridge Corporation (RPXC-US, FH-US, ACTG-US, CHTR-US and LTBR-US) that have also reported ... Read more (Read more...)

  • Spherix Announces Economic Interest Acquired in New Patent Portfolio
    PR Newswire8 months ago

    Spherix Announces Economic Interest Acquired in New Patent Portfolio

    Spherix and its partner Equitable IP Corporation have acquired an economic interest and the right to monetize a valuable portfolio in the fiber optic technology space as part of their ongoing patent monetization efforts.

  • Spherix, Inc. :SPEX-US: Earnings Analysis: Q4, 2016 By the Numbers : April 7, 2017
    Capital Cube8 months ago

    Spherix, Inc. :SPEX-US: Earnings Analysis: Q4, 2016 By the Numbers : April 7, 2017

    Categories: Yahoo FinanceGet free summary analysis Spherix, Inc. reports financial results for the quarter ended December 31, 2016. Highlights Summary numbers: Revenues of USD 0.31 million, Net Earnings of USD -3.90 million. Change in operating cash flow of 7.84% compared to same period last year is about the same as change in earnings, likely no significant movement ... Read more (Read more...)

  • Benzinga9 months ago

    Your Guide To Patent Play Exposure

    Litigations more often trigger strong stock moves, and this was evident in the rally by the shares of ParkerVision, Inc. (NASDAQ: PRKR ) last Wednesday. ParkerVision Goes 4 Up Over Qualcomm ParkerVision ...

  • PR Newswire10 months ago

    Spherix Announces New Clients in the $100B Online Learning Business

    NEW YORK, Feb. 21, 2017 /PRNewswire/ -- Spherix Incorporated (SPEX) an intellectual property development company committed to the fostering of technology and monetization of intellectual property, today announced that it has signed up a new client to its Patent Monetization and Consulting subsidiary. Spherix has entered into an IP Consulting Services Agreement with Numedeon and VWIP Inc.  Numedeon Inc. is a privately held company based in Pasadena, California, that since 1999 has been developing immersive online digital learning technology.

  • PR Newswire11 months ago

    Spherix Updates Shareholders

    NEW YORK, Jan. 23, 2017 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) an intellectual property development company committed to the fostering of technology and monetization of intellectual property, ...